Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Bilastine 20 mg Oral Dispersible Tablets in Healthy Adults
NCT07042828Phase 1Completed
- Sponsor
- Humanis
- Start
- Apr 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bilastine in allergic rhinoconjunctivitis (ARC) and urticaria (2 arms), sponsored by Humanis. Primary endpoints: Peak Plasma Concentration at 24 hours and Area Under the Curve from time zero to time of last measurable concentration at 24 hours. Started Apr 2025; status: completed.
02
Drugs
bilastine
03
Conditions
allergic rhinoconjunctivitis (ARC)urticaria
Beyond the preview
Go deeper on NCT07042828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07042828.